Rhythm pharmaceuticals, inc. (RYTM)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Dec'16
Assets
Current assets:
Cash and cash equivalents

55,776

62,294

71,680

63,118

42,020

49,542

58,247

210,484

43,167

34,236

27,914

6,540

Short-term investments

201,648

230,165

90,755

132,049

179,503

202,519

214,139

77,070

-

113,846

2,501

3,997

Prepaid expenses and other current assets

10,436

9,945

8,442

8,334

8,646

6,628

4,152

3,217

1,961

2,589

1,621

638

Total current assets

267,860

302,404

170,877

203,501

230,169

258,689

276,538

290,771

138,414

150,671

32,036

11,175

Property and equipment, net

3,504

3,671

3,862

3,901

2,757

1,120

939

728

779

840

845

930

Right-of-use asset

1,989

2,045

2,097

3,085

3,174

-

-

-

-

-

-

-

Deferred issuance costs

-

-

295

-

-

-

-

-

-

-

1,698

9

Restricted cash

403

403

402

401

402

401

251

250

250

225

225

225

Total assets

273,756

308,523

177,533

210,888

236,502

260,210

277,728

291,749

139,443

151,736

34,804

12,339

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

5,932

10,415

7,745

6,565

3,992

7,640

208

3,312

2,456

2,427

2,271

1,895

Due to related party

-

-

-

-

-

-

-

-

-

-

-

105

Deferred rent

-

-

-

-

-

-

-

86

85

83

81

76

Accrued expenses and other current liabilities

11,277

13,530

17,005

19,146

8,373

5,942

7,595

3,849

3,038

4,210

3,108

2,655

Lease liability

487

472

457

379

202

-

-

-

-

-

-

-

Total current liabilities

17,696

24,417

25,207

26,090

12,567

13,582

7,803

7,247

5,579

6,720

5,460

4,731

Long-term liabilities:
Lease liability

-

-

3,211

3,331

3,446

-

-

-

-

-

-

-

Deferred rent

2,959

3,086

-

-

-

372

288

185

206

228

250

311

Total liabilities

20,655

27,503

28,418

29,421

16,013

13,954

8,091

7,432

5,785

6,948

5,710

5,042

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

Stockholders’ equity:
Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

-

-

-

-

-

-

0

0

0

-

80,950

40,000

Common stock, $0.001 par value: 120,000,000 shares authorized; 44,088,390 and 43,996,753 shares issued and outstanding March 31, 2020 and December 31, 2019, respectively

44

44

35

34

34

34

34

34

27

27

2

10

Series A-1 Convertible Junior Preferred Stock, $0.001 par value, 78,666,209 shares authorized; 78,666,209 and no shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively

-

-

-

-

-

-

-

-

-

-

79

-

Additional paid-in capital

612,552

606,307

441,455

437,805

434,031

430,824

428,698

425,406

260,342

255,013

47,784

43,830

Accumulated deficit

-359,495

-325,331

-292,375

-256,372

-213,576

-184,602

-159,095

-141,123

-126,711

-110,252

-99,721

-76,543

Total stockholders’ equity

253,101

281,020

149,115

181,467

220,489

246,256

269,637

284,317

133,658

144,788

-51,856

-32,703

Total liabilities and stockholders’ equity

273,756

308,523

177,533

210,888

236,502

260,210

277,728

291,749

139,443

151,736

34,804

12,339